Celcuity Inc. (CELC)
- Sector
- Biotechnology
- Last price
- $63.19
- As of
Kresmion compiles this page from CELC's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Celcuity Inc. (CELC): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-02.
See the full CELC dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CELC on one page. Preview it with sample data, then open it live with a free account.
Preview the CELC dossierActive signals for CELC
- highCONSENSUS_BUY
5 tracked funds increased CELC this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +416% to CELC (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +418% to CELC (2026Q2)
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in CELC
- highCONSENSUS_BUY
3 tracked funds increased CELC this 2026Q2, institutional consensus
FREE, NO ACCOUNT
Every signal on CELC, as it fires
You are seeing 5 of 19 signals recorded on CELC since 2026-05-26.
The five above all landed on 2026-08-16. The other 14 were recorded on 3 other days. 12 of the 19 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CELC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 15102K100 · 2026Q2 | $68.1M | 0.08% | , |
| CITADEL ADVISORS LLCCUSIP 15102KAB6 · 2026Q2 | $20.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 15102KAB6 · 2026Q2 | $9.7M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 15102KAB6 · 2026Q2 | $9.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 15102K100 · 2026Q2 | $3.2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 15102KAA8 · 2026Q2 | $789K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CELC
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CELC against its peers
CELC's return on equity of -176.1% ranks in the 10th percentile of 24 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | CELC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 62.4M | n/a | 19 |
| Operating margin | n/a | -178.4% | n/a | 17 |
| Net margin | n/a | -57.2% | n/a | 17 |
| Return on equity | -176.1% | -29.5% | 10 | 24 |
| 1 year | 33.3% | 26.5% | 57 | 19 |
Peers (24): ARQT, GRTX, ACAD, IDYA, XENE, DNLI, DYN, RCUS, LEGN, VKTX, VCYT, ELVN, TLX, CPRX, RLAY, ZLAB, PGEN, TNGX, ATAI, BEAM, EWTX, MBX, NAMS, DNTH. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CELC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CELC on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CELC for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.